ANEBAnebulo Pharmaceuticals, Inc.

Nasdaq anebulo.com


$ 1.99 $ 0.06 (3.03 %)    

Monday, 05-Aug-2024 13:29:33 EDT
QQQ $ 480.15 $ -1.15 (-0.24 %)
DIA $ 408.54 $ -0.35 (-0.09 %)
SPY $ 558.65 $ -0.51 (-0.09 %)
TLT $ 98.68 $ 0.38 (0.39 %)
GLD $ 232.46 $ -1.26 (-0.54 %)
$ 1.9799
$ 1.45 x 100
-- x --
-- - --
$ 1.62 - $ 4.05
7,331
na
52.9M
$ 0.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 02-13-2024 12-31-2023 10-Q
3 11-14-2023 09-30-2023 10-Q
4 09-22-2023 06-30-2023 10-K
5 05-11-2023 03-31-2023 10-Q
6 02-10-2023 12-31-2022 10-Q
7 11-10-2022 09-30-2022 10-Q
8 09-09-2022 06-30-2022 10-K
9 05-11-2022 03-31-2022 10-Q
10 02-11-2022 12-31-2021 10-Q
11 11-12-2021 09-30-2021 10-Q
12 09-22-2021 06-30-2021 10-K
13 06-21-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 anebulo-receives-19m-grant-from-nida-for-investigational-iv-treatment-of-cannabis-toxic-effects

 The grant comes in the form of two tranches with the initial award of $0.9 million and subsequent funding of approximately $1 ...

 anebulo-pharmaceuticals-q3-eps-006-beats-012-estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate ...

 substance-use-disorder-company-narrows-q2-net-loss-reports-progress-on-cannabinoid-intoxication-drug

Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday secon...

 anebulo-pharmaceuticals-q2-eps-011-misses-010-estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimat...

 anebulo-pharmaceuticals-filed-us-patent-application-20240010617-crystalline-forms-of-a-cannabinoid-receptor-type-1-cb1-modulator-and-methods-of-use-and-preparation-thereof

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240010617<p> Float: 3,912,399

 anebulo-pharmaceuticals-q1-eps-010-beats-012-estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate ...

 why-servisfirst-bancshares-shares-are-trading-lower-by-6-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent...

 anebulo-pharmaceuticals-incs-richie-cunningham-announced-as-chief-executive-officer-and-member-of-anebulos-board-of-directors

- Reuters

 benchmark-reiterates-speculative-buy-on-anebulo-pharmaceuticals-maintains-8-price-target

Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and maintains $8 ...

 on-september-26-2023-anebulo-pharmaceuticals-appointed-daniel-george-as-the-companys-part-time-cfo-principal-financial-officer-and-principal-accounting-officer-effective-september-28-replacing-sandra-gardiner---8k

https://www.sec.gov/ix?doc=/Archives/edgar/data/1815974/000149315223034696/form8-k.htm

 hc-wainwright--co-reiterates-buy-on-anebulo-pharmaceuticals-maintains-6-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy and maintains...

 maxim-group-initiates-coverage-on-anebulo-pharmaceuticals-with-buy-rating-announces-price-target-of-6

Maxim Group analyst Michael Okunewitch initiates coverage on Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy rating and ann...

 anebulo-pharmaceuticals-q4-eps-010-beats-012-estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION